In short
Clinical trials are investigating VENT-03 in adults with active cutaneous lupus erythematosus, with or without systemic lupus erythematosus. These studies aim to evaluate efficacy and safety, including changes in skin-related disease activity and immune signals in the skin.
Key points
- Clinical trials are studying VENT-03 in adults with active cutaneous lupus erythematosus, including some people who also have systemic lupus erythematosus. The main study is a Phase 2a trial, which means it is an early mid-stage trial looking at both possible benefit and safety. The trial compares VENT-03 with placebo in a randomized, double-blind design. The main outcome is the change in the IFN gene signature in the skin after 28 days. The study is authorised and plans to enroll 23 participants.
Trial overview
The available study is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial of VENT-03 in adults with active cutaneous lupus erythematosus, with or without systemic lupus erythematosus.
The study is designed to evaluate the efficacy and safety of VENT-03, and it also includes an open-label extension part.
Who can participate
This trial is for adult participants with active cutaneous lupus erythematosus.
People may join whether or not they also have systemic lupus erythematosus, so the study includes a broader lupus population than skin disease alone.
Study design and treatment groups
Participants are assigned to study groups by chance in a randomized design, which helps make the comparison fair.
The trial is double-blind, which means the participants and the study team do not know who receives VENT-03 or placebo during the blinded part of the study.
The placebo tablets are made from the same excipients found in VENT-03 tablets and are identical in appearance, so the comparison is more reliable.
The study also includes an open-label extension, which is a follow-up period where treatment is no longer hidden and participants can continue in the study.
What is being measured
The main endpoint is the percent change from baseline in the IFN gene signature in the skin at Day 28.
This means the study looks at how much the skin immune signal changes after treatment compared with the starting point before the study began.
The brief summary says the trial is evaluating the effect of VENT-03 on the interferon gene signature in the skin, which shows that the study is focused on a skin-based immune marker.
Trial status and size
The trial status is Authorised, and the planned enrollment is 23 participants.
This is a small Phase 2 study, so it is mainly meant to learn more about possible benefit and safety in the target group before larger studies, if needed.